{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:42:17Z","timestamp":1770748937992,"version":"3.50.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T00:00:00Z","timestamp":1223596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T00:00:00Z","timestamp":1223596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00432-008-0496-x","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T13:52:24Z","timestamp":1223560344000},"page":"617-625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area"],"prefix":"10.1007","volume":"135","author":[{"given":"Ju Hyun","family":"Shim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joong-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon-Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum Joon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,10]]},"reference":[{"key":"496_CR1","doi-asserted-by":"publisher","unstructured":"(1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28(3):751\u2013755 doi:10.1002\/hep.510280322","DOI":"10.1002\/hep.510280322"},{"key":"496_CR2","unstructured":"(2006) Annual Report Cause of Death 2005. National Statistical Office"},{"issue":"26","key":"496_CR3","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293\u20134300","journal-title":"J Clin Oncol"},{"issue":"10","key":"496_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/jjco\/hym095","volume":"37","author":"H Akaza","year":"2007","unstructured":"Akaza H, Tsukamoto T et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37(10):755\u2013762","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"496_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/jhep.2002.32089","volume":"35","author":"J Bruix","year":"2002","unstructured":"Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35(3):519\u2013524","journal-title":"Hepatology"},{"issue":"3","key":"496_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421\u2013430","journal-title":"J Hepatol"},{"issue":"5","key":"496_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208\u20131236","journal-title":"Hepatology"},{"key":"496_CR8","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/jco.2008.26.15_suppl.4509","volume":"26","author":"A Cheng","year":"2008","unstructured":"Cheng A, Kang Y et al (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 26:May 20 suppl; abstr 4509","journal-title":"J Clin Oncol"},{"issue":"1","key":"496_CR9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse J, Ishii H et al (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99(1):159\u2013165","journal-title":"Cancer Sci"},{"issue":"20","key":"496_CR10","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1038\/sj.onc.1204372","volume":"20","author":"S Giambartolomei","year":"2001","unstructured":"Giambartolomei S, Covone F et al (2001) Sustained activation of the Raf\/MEK\/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 20(20):2606\u20132610","journal-title":"Oncogene"},{"issue":"4","key":"496_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"5","key":"496_CR12","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171","journal-title":"Hepatology"},{"issue":"2","key":"496_CR13","first-page":"88","volume":"10","author":"JW Park","year":"2004","unstructured":"Park JW (2004) Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 10(2):88\u201398","journal-title":"Korean J Hepatol"},{"issue":"12","key":"496_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00432-007-0232-y","volume":"133","author":"JW Park","year":"2007","unstructured":"Park JW, An M et al (2007) Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 133(12):937\u2013943","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"496_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1440-1746.2007.05112.x","volume":"23","author":"KW Park","year":"2008","unstructured":"Park KW, Park JW et al (2008) Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 23(3):467\u2013473","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"496_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","volume":"2","author":"DM Parkin","year":"2001","unstructured":"Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533\u2013543","journal-title":"Lancet Oncol"},{"issue":"7","key":"496_CR17","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.bmcl.2007.01.046","volume":"17","author":"P Raboisson","year":"2007","unstructured":"Raboisson P, Lenz O et al (2007) Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett 17(7):1843\u20131849","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"496_CR18","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","volume":"22","author":"MJ Ratain","year":"2004","unstructured":"Ratain MJ, Eckhardt SG (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22(22):4442\u20134445","journal-title":"J Clin Oncol"},{"issue":"5","key":"496_CR19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0360-3016(00)00519-8","volume":"47","author":"J Seong","year":"2000","unstructured":"Seong J, Park HC et al (2000) Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 47(5):1331\u20131335","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"496_CR20","doi-asserted-by":"crossref","unstructured":"Shim JH, Park JW et al (2008) Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol (Epub ahead of print)","DOI":"10.1007\/s00280-008-0759-x"},{"issue":"3","key":"496_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"496_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1386-6346(02)00144-4","volume":"24","author":"S Ueno","year":"2002","unstructured":"Ueno S, Tanabe G et al (2002) Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 24(4):395\u2013403","journal-title":"Hepatol Res"},{"issue":"2","key":"496_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu S, Chen JJ et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117\u2013123","journal-title":"Lancet Oncol"},{"issue":"2","key":"496_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cncr.23175","volume":"112","author":"AX Zhu","year":"2008","unstructured":"Zhu AX (2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112(2):250\u2013259","journal-title":"Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0496-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-008-0496-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0496-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0496-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T13:45:57Z","timestamp":1709300757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-008-0496-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["496"],"URL":"https:\/\/doi.org\/10.1007\/s00432-008-0496-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,10]]},"assertion":[{"value":"10 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}